StockpollyBeta
Get App
Delisting riskPopularity #4,349
JUNS · NASDAQ · Biotechnology

Jupiter Neurosciences (JUNS)

Develops CNS drug candidates and sells Nugevia longevity supplements.

$2.92
vs last close−0.06 (−2.01%)

  1. Jupiter Neurosciences announces pricing of $2M registered direct offering

    The FlyFinancing

  2. Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

    GlobeNewsWireFinancing

  3. Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

    BenzingaMarket move

  4. Jupiter Neurosciences, Inc. Announces Reverse Stock Split

    Globe News Wire

  5. Jupiter Neurosciences, Inc. Announces Reverse Stock Split

    GlobeNewsWire

  6. Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

    Globe News Wire

  7. Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

    GlobeNewsWire

  8. Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

    GlobeNewsWire

  9. Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

    GlobeNewsWire

  10. D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

    Accesswire

  11. Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

    GlobeNewsWire

  12. Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

    Globe News Wire

  13. Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

    GlobeNewsWire

  14. Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

    Benzinga

  15. PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

    GlobeNewsWire

  16. Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

    Globe News Wire

  17. Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

    GlobeNewsWire

  18. Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

    Newsfile Corp

  19. Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Increase in Short Interest

    Defense World

  20. Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

    Newsfile Corp

  21. Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS

    Business Wire

  22. Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS

    Business Wire

  23. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

    GlobeNewsWire

  24. Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

    GlobeNewsWire